WESTON, Fla., March 06, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, today announced that it has entered into a securities purchase agreement with a single healthcare-focused U.S. institutional investor for the purchase and sale of 2,105,265 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 2,105,265 shares of common stock at an effective combined price of $0.95 per share and common warrant for aggregate gross proceeds of approximately $2.0 million, before deducting placement agent fees and other offering expenses.
KEY HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease on track to begin H2-2024. Obesity with related metabolic complications selected as lead indication for Inflammasome ASC Inhibitor IC 100.
ZyVersa CEO will discuss development milestones for Cholesterol Efflux Mediator VAR 200 and Inflammasome ASC Inhibitor IC 100 at BIO CEO & Investor Conf.
ZyVersa Therapeutics (NASDAQ: ZVSA ) stock is sliding lower on Thursday after the clinical-stage biopharmaceutical company priced a public share offering. ZyVersa Therapeutics is offering 4 million shares of ZVSA stock at a price of $1.25 each.
ZyVersa Therapeutics (NASDAQ: ZVSA ) stock is rising higher on Wednesday after the clinical-stage specialty biopharmaceutical company highlighted the publication of a paper in a peer-reviewed journal. That paper, titled “Hematopoietic NLRP3 and AIM2 inflammasomes promote diabetes-accelerated atherosclerosis, but increased necrosis is independent of pyroptosis,” was published in Diabetes.
ZyVersa Therapeutics (NASDAQ: ZVSA ) stock is sliding lower on Wednesday following a couple of announcements from the company. The first is the company's publication of an article in the peer-reviewed Journal of Neuroinflammation.
WESTON, Fla., April 11, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of renal and inflammatory diseases with high unmet medical needs, announces that Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President, will present at Planet MicroCap Showcase 2023 being held in Las Vegas April 25-27.
ZyVersa Therapeutics (NASDAQ: ZVSA ) stock is taking off on Thursday without any recent news from the biopharmaceutical company. Instead, it looks like investors can thank heavy pre-market trading for the ZVSA stock's rise this morning.